Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?

Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?

Jeff Lewis

Fri, September 18, 2026 at 12:14 AM GMT+3 4 min read

• KMTS +0.33%

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026.

Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, but the expanding organization still consumes substantially more than the business generates in gross profit.

Bull Case

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) attributed revenue growth to wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher proportion of in-network patients and improvements in revenue cycle management.

These drivers suggest several ways to expand: reach more patients, improve reimbursement outcomes, and collect revenue more effectively. Their investment value depends on sustaining growth without requiring a matching increase in support costs.

Gross profit nearly doubled to $17.5 million from $8.9 million. Management attributed the margin improvement to higher volume, the in-network patient mix, and cost initiatives. The company is retaining more of each revenue dollar to fund selling expenses and product development.

The quarterly filing adds useful detail: cost of revenue per patient fell 9%, reflecting better use of the rental-equipment pool, lower disposable costs and longer estimated equipment-component lives. The latter reduced depreciation by approximately $0.3 million. The improvement therefore combines operating efficiencies with an accounting-estimate benefit.

Gross profit grew approximately 98%, compared with 46% growth in GAAP operating expenses. That percentage relationship supports the possibility of operating leverage as the revenue base expands.

Bear Case

The dollar comparison shows how much work remains. GAAP operating expenses increased to $55.2 million from $37.7 million. Using unrounded figures, the $8.6 million gross-profit increase covered only about half of the $17.4 million increase in operating expenses. Operating loss widened to $37.7 million from $28.9 million.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) also reported company-defined non-GAAP adjusted operating expenses of $44.2 million, versus $30.3 million. This measure excludes share-based compensation and nonrecurring expenses. Management attributed the increase primarily to commercial expansion and accelerated investment in research and development.

The spending increase therefore extends beyond the excluded items. New territories must become more productive as they mature, while development investments must ultimately support additional revenue or stronger margins.

GAAP net loss widened to $44.1 million from $25.8 million, including a $6.3 million debt-extinguishment loss associated with early repayment of the previous loan. That charge contributed to the deterioration, alongside the larger operating loss.

Operating cash outflow increased to $32.3 million from $26.3 million, with another $8.3 million spent on property and equipment. Cash, equivalents and investments totaled $244.7 million, down from $262.2 million at April 30.

Liquidity also benefited from $22.5 million of net financing inflows, primarily from refinancing that involved $75 million of new borrowing, offset by debt repayment and related costs. The balance provides funding capacity, while continuing cash consumption keeps execution discipline important.

Hedge Fund Sentiment

The filings available so far reflect positions held before Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported its fiscal 2027 first-quarter results. Insider Monkey's database showed 15 hedge funds holding Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) at the end of 2Q2026, up from 12 funds three months earlier.

Conclusion

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) is improving its commercial economics, but higher margins have yet to narrow operating losses. In our view, the decisive test is whether additional gross-profit dollars consistently exceed additional operating expenses. Patient growth, reimbursement collections, territory productivity, and cash consumption will show whether the business can scale profitably.

While we acknowledge the potential of KMTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: CBRE Group (CBRE) Unit Buys $1.6 Billion Net-Lease Platform. Can Scale Lift Fee Earnings? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?

This article is originally published at Insider Monkey.